These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 21878851)

  • 1. Association between high-risk disease loci and response to anti-vascular endothelial growth factor treatment for wet age-related macular degeneration.
    Orlin A; Hadley D; Chang W; Ho AC; Brown G; Kaiser RS; Regillo CD; Godshalk AN; Lier A; Kaderli B; Stambolian D
    Retina; 2012 Jan; 32(1):4-9. PubMed ID: 21878851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic influences on the outcome of anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration.
    Abedi F; Wickremasinghe S; Richardson AJ; Islam AF; Guymer RH; Baird PN
    Ophthalmology; 2013 Aug; 120(8):1641-8. PubMed ID: 23582991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT).
    Hagstrom SA; Ying GS; Pauer GJT; Sturgill-Short GM; Huang J; Callanan DG; Kim IK; Klein ML; Maguire MG; Martin DF;
    Ophthalmology; 2013 Mar; 120(3):593-599. PubMed ID: 23337555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetic associations with long-term response to anti-vascular endothelial growth factor treatment in neovascular AMD patients.
    Park UC; Shin JY; McCarthy LC; Kim SJ; Park JH; Chung H; Yu HG
    Mol Vis; 2014; 20():1680-94. PubMed ID: 25558172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CFH, VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration.
    McKibbin M; Ali M; Bansal S; Baxter PD; West K; Williams G; Cassidy F; Inglehearn CF
    Br J Ophthalmol; 2012 Feb; 96(2):208-12. PubMed ID: 21558292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetic influence of LOC387715/HTRA1 on the efficacy of bevacizumab treatment for age-related macular degeneration in a Korean population.
    Kang HK; Yoon MH; Lee DH; Chin HS
    Korean J Ophthalmol; 2012 Dec; 26(6):414-22. PubMed ID: 23204795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of choroidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials.
    Maguire MG; Daniel E; Shah AR; Grunwald JE; Hagstrom SA; Avery RL; Huang J; Martin RW; Roth DB; Castellarin AA; Bakri SJ; Fine SL; Martin DF;
    Ophthalmology; 2013 Oct; 120(10):2035-41. PubMed ID: 23706946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetics of the treatment response of age-related macular degeneration with ranibizumab and bevacizumab.
    Kanoff J; Miller J
    Semin Ophthalmol; 2013; 28(5-6):355-60. PubMed ID: 24010796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. VEGFA and VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT).
    Hagstrom SA; Ying GS; Pauer GJ; Sturgill-Short GM; Huang J; Maguire MG; Martin DF;
    JAMA Ophthalmol; 2014 May; 132(5):521-7. PubMed ID: 24652518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cumulative effect of risk alleles in CFH, ARMS2, and VEGFA on the response to ranibizumab treatment in age-related macular degeneration.
    Smailhodzic D; Muether PS; Chen J; Kwestro A; Zhang AY; Omar A; Van de Ven JP; Keunen JE; Kirchhof B; Hoyng CB; Klevering BJ; Koenekoop RK; Fauser S; den Hollander AI
    Ophthalmology; 2012 Nov; 119(11):2304-11. PubMed ID: 22840423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenomics of response to anti-VEGF therapy in exudative age-related macular degeneration.
    Dedania VS; Grob S; Zhang K; Bakri SJ
    Retina; 2015 Mar; 35(3):381-91. PubMed ID: 25635578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complement factor H and high-temperature requirement A-1 genotypes and treatment response of age-related macular degeneration.
    Tsuchihashi T; Mori K; Horie-Inoue K; Gehlbach PL; Kabasawa S; Takita H; Ueyama K; Okazaki Y; Inoue S; Awata T; Katayama S; Yoneya S
    Ophthalmology; 2011 Jan; 118(1):93-100. PubMed ID: 20678803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age-related macular degeneration in the IVAN Study.
    Lotery AJ; Gibson J; Cree AJ; Downes SM; Harding SP; Rogers CA; Reeves BC; Ennis S; Chakravarthy U;
    Ophthalmology; 2013 Dec; 120(12):2637-2643. PubMed ID: 24070809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic association with response to intravitreal ranibizumab for neovascular age-related macular degeneration in the Han Chinese population.
    Yuan D; Yuan D; Liu X; Yuan S; Xie P; Liu Q
    Ophthalmologica; 2013; 230(4):227-32. PubMed ID: 24080590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Association between Y402H, E318D and R102G polymorphisms of complement proteins genes and the response to intravitreal anti-VEGF treatment in patients with neovascular age-related macular degeneration].
    Kubicka-Trząska A; Karska-Basta I; Kobylarz J; Dziedzina S; Sanak M; Romanowska-Dixon B
    Klin Oczna; 2016; 118(2):114-21. PubMed ID: 29912491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetics in neovascular age-related macular degeneration susceptibility and treatment response to anti-VEGF intravitreal injection: A case series study.
    Chang FY; Huang CH; Yang CH; Chang JT; Yang CM; Ho TC; Hsieh YT; Lai TT; Lin CW; Lin CP; Chen YC; Lai YJ; Chen PL; Hsu JS; Chen TC
    Clin Exp Ophthalmol; 2024 Aug; 52(6):655-664. PubMed ID: 38757252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of genetic polymorphisms with response to bevacizumab for neovascular age-related macular degeneration in the Chinese population.
    Tian J; Qin X; Fang K; Chen Q; Hou J; Li J; Yu W; Chen D; Hu Y; Li X
    Pharmacogenomics; 2012 May; 13(7):779-87. PubMed ID: 22594510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Single-Nucleotide Polymorphisms in Age-Related Macular Degeneration With Pseudodrusen: Secondary Analysis of Data From the Comparison of AMD Treatments Trials.
    Lin LY; Zhou Q; Hagstrom S; Maguire MG; Daniel E; Grunwald JE; Martin DF; Ying GS;
    JAMA Ophthalmol; 2018 Jun; 136(6):682-688. PubMed ID: 29801032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suggestive association between PLA2G12A single nucleotide polymorphism rs2285714 and response to anti-vascular endothelial growth factor therapy in patients with exudative age-related macular degeneration.
    Wang VM; Rosen RB; Meyerle CB; Kurup SK; Ardeljan D; Agron E; Tai K; Pomykala M; Chew EY; Chan CC; Tuo J
    Mol Vis; 2012; 18():2578-85. PubMed ID: 23112570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic association with response to intravitreal ranibizumab in patients with neovascular AMD.
    Kloeckener-Gruissem B; Barthelmes D; Labs S; Schindler C; Kurz-Levin M; Michels S; Fleischhauer J; Berger W; Sutter F; Menghini M
    Invest Ophthalmol Vis Sci; 2011 Jul; 52(7):4694-702. PubMed ID: 21282580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.